Nihal Sinha, M.D.

Partner

+44 207 074 5848

About

Nihal is a Partner at F-Prime Capital based in the London office and focuses primarily on biotech and healthcare IT in Europe. At F-Prime Nihal has been involved in a number of cell and gene therapy investments including as a member of the founding team of Orchard Therapeutics. Prior to joining F-Prime in 2013, he worked as a strategy consultant at BCG and as an academic physician at Oxford University and UCL Hospitals.

Nihal holds a MB BChir with distinction from the University of Cambridge and is a Member of the Royal College of Physicians.

  • Adaptimmune (NASDAQ: ADAP) is a cellular therapeutics company developing affinity enhanced T-cell receptor (TCR) engineered T-cells to treat solid tumor and hematological cancers. Learn more at www.adaptimmune.com.

  • Affinia Therapeutics is a gene therapy company with a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies and a mission to develop transformative medicines for devastating diseases. Learn more at www.affiniatx.com.

  • AviadoBio is a pioneering gene therapy company focused on developing and delivering transformative medicines for people living with neurodegenerative disorders. Learn more at www.aviadobio.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      London, UK and New Jersey, US

    • Year Invested

      2020

    • Team

  • Buoy is an online symptom and cure checker that uses an intelligent algorithm backed by medical data to diagnose patients. Learn more at www.buoyhealth.com.

  • Caribou (NASDAQ:CRBU) is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. Caribou’s proprietary technologies put the company at the forefront of the development of new medical therapies. Learn more at www.cariboubio.com.

  • CHARM Therapeutics is a 3D deep-learning research Company discovering and developing transformational medicines. Based on the award-winning discoveries of David Baker in protein-folding, CHARM has developed a proprietary technology based on the first rapid, accurate protein/ligand co-folding algorithm. The Company’s mission is to use these insights to address challenging targets in cancer and other disease areas and discover and develop new drugs against these targets. Learn more at www.charmtx.com.

     

  • Cipla Health focuses on developing and commercializing products in the consumer healthcare and over-the-counter categories. Learn more at www.ciplahealth.in.

  • CORE provides high-end diagnostics services for disease stratification and therapy selection. Learn more at www.corediagnostics.in.

  • Elucidata was founded in 2015 by University of Chicago and MIT graduate Dr. Abhishek Jha and IIT Delhi alumnus Swetabh Pathak. The company’s cutting-edge platform Polly operates on unique Bio-NLP technology that cleans and links 26+ R&D data types and caters to companies in various stages of their drug discovery process. The platform helps data science teams scale by providing them 70 TB of ML-Ready biomedical data, from ~30 public and proprietary sources. Today, 3 of the top 10 pharmaceutical companies are using Polly to fast track their R&D initiatives. Learn more at www.elucidata.io.

    • Category

      • Health IT/Services
    • Status

      • Private
    • Location

      Cambridge, MA

    • Year Invested

      2022

    • Team

  • Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g. chemotherapy). Learn more at www.ensoma.com.

  • Immuneel is a pioneering clinical stage start-up company leading the change in cell & gene therapies & personalized immunotherapy for patients in India. Headquartered in Bengaluru, Karnataka, India, Immuneel is a research-led, fully integrated cell & gene therapies company committed to bringing breakthrough cancer treatments to India, affordably & build a portfolio of next generation cell therapies. Learn more at www.immuneel.com.

     

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      Bangaluru, India

    • Year Invested

      2019

    • Team

  • Indalo Therapeutics, a preclinical biotechnology company dedicated to developing therapies for fibrosis, is formed with an experienced team, strong IP, and robust portfolio of drug candidates. Learn more at www.indalotherapeutics.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      St. Louis, MO

    • Year Invested

      2017

    • Team

  • Leyden Labs platform targets commonalities of viral families to protect humanity from known and future viruses. Learn more at www.leydenlabs.com.

  • Orchard Therapeutics (NASDAQ:ORTX) Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Learn more at www.orchard-tx.com.

  • Oviva is a new type of healthcare provider using technology to scale the dietitian workforce to help meet the growing number of patients with diet-related health conditions. Learn more at www.oviva.com/uk/.

  • Proximie is a technology platform that uses a combination of machine learning, artificial intelligence and augmented reality to allow clinicians to virtually ‘scrub in’ and collaborate with each other from anywhere in the world.  Learn more at proximie.com.

  • RIGImmune is a platform biopharmaceutical company developing a novel investigational class of RNA immunotherapies termed “SLRs” for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The RIGImmune development candidates act to specifically modulate RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The lead development candidate at RIGImmune is RIG-101.

    The company was co-founded by the prominent Yale University professors, Anna Marie Pyle, Ph.D. and Akiko Iwasaki, Ph.D., who currently serve as scientific advisors to the company. Dr. Pyle co-discovered the RIG-I receptor family and conducted many of the first structural and biochemical investigations on the cytosolic protein, RIG-I. Dr. Pyle is also a specialist in RNA structure and design. She designed the stem-loop RNA therapeutics (SLR) for selective targeting of RIG-I using crystal structure data of RIG-I complexed with RNA and developed them as antitumor and anticancer compounds in collaboration with Dr. Iwasaki, whose expertise in mucosal immunity has been highly sought during the COVID-19 pandemic.

    RIGImmune is a UConn Technology Incubation Program (TIP) company located in Farmington, CT, was founded by Yale scientists, and has an experienced management team of successful biotech entrepreneurs and world-renowned scientists. Learn more at rigimmune.com.

  • Sana Biotechnology, Inc. (NASDAQ:SANA) is focused on creating and delivering engineered cells as medicine for patients. We are a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and changes how we approach treating disease. Learn more about Sana at www.sana.com.

  • Turnstone Biologics is transforming patient care with a new class of targeted viral immunotherapies to fight cancer.  Learn more at www.turnstonebio.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      Ottawa, Canada

    • Year Invested

      2016

    • Team